Clinical Trial Update: An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery [Phase 2]

View source ↗

Summary

Completion of a Phase 2 trial evaluating two dosing regimens of AP214 to prevent kidney injury in patients undergoing cardiac surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• AP214 (AP214)

Snippet

Sponsor: Action Pharma A/S | Conditions: Cardiac Surgery, Coronary Artery Bypass | Phase 2 | Status: COMPLETED